passages: 2560
passages: document
passages: A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer . Uncertainty remains about the optimal anti-emetic regimen for control of delayed nausea and vomiting after adjuvant chemotherapy for breast cancer . Many patients receive dexamethasone but complain of insomnia , anxiety/agitation , and indigestion . The aim was to determine if patients receiving chemotherapy for breast cancer prefer treatment with dexamethasone or placebo for prophylaxis against delayed nausea and vomiting , and to compare quality of life ( QOL ) between the two treatments . In this randomized , double-blind , cross-over trial , we compared oral dexamethasone ( 4 mg twice daily for 2 days ) versus placebo for chemotherapy-naïve patients with breast cancer . All patients received intravenous granisetron and dexamethasone pre-chemotherapy and oral granisetron on day 2 . Primary endpoints were : ( i ) patient preference ; ( ii ) difference between cycles in change of QOL from days 1 to 8 . Median age of the 94 women was 51 years ( range 27-76 ) : 79 received fluorouracil/epirubicin/cyclophosphamide and 15 received doxorubicin/cyclophosphamide . Thirteen withdrew pre-cycle 2 with no differences between arms . Of 80 patients stating a preference , 31 preferred placebo ( 39 % , 95 % CI : 28-50 % ) and 37 ( 46 % , 95 % CI : 35-58 % ) preferred dexamethasone ; 12 had no preference . There were no differences in intensity of vomiting , nausea , or time to onset of vomiting . There was greater decrease in global QOL ( p = 0.06 ) when patients received dexamethasone . No other symptom/QOL domains differed significantly . In conclusion , no significant difference was found in patient preference , QOL , or symptoms regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy .
entities: 2561
entities: Intervention_Control
entities: placebo-controlled
entities: 2562
entities: Intervention_Pharmacological
entities: dexamethasone
entities: 2563
entities: Intervention_Pharmacological
entities: chemotherapy
entities: 2564
entities: Intervention_Pharmacological
entities: chemotherapy
entities: 2565
entities: Intervention_Pharmacological
entities: dexamethasone
entities: 2566
entities: Intervention_Pharmacological
entities: chemotherapy
entities: 2567
entities: Intervention_Pharmacological
entities: dexamethasone
entities: 2568
entities: Intervention_Control
entities: placebo
entities: 2569
entities: Intervention_Pharmacological
entities: dexamethasone
entities: 2570
entities: Intervention_Control
entities: placebo
entities: 2571
entities: Intervention_Pharmacological
entities: granisetron
entities: 2572
entities: Intervention_Pharmacological
entities: dexamethasone pre-chemotherapy
entities: 2573
entities: Intervention_Pharmacological
entities: granisetron
entities: 2574
entities: Intervention_Pharmacological
entities: fluorouracil/epirubicin/cyclophosphamide
entities: 2575
entities: Intervention_Pharmacological
entities: doxorubicin/cyclophosphamide
entities: 2576
entities: Intervention_Control
entities: placebo
entities: 2577
entities: Intervention_Pharmacological
entities: dexamethasone
entities: 2578
entities: Intervention_Pharmacological
entities: dexamethasone
entities: 2579
entities: Intervention_Pharmacological
entities: dexamethasone
entities: 2580
entities: Outcome_Physical
entities: quality of life
entities: 2581
entities: Outcome_Mental
entities: quality of life ( QOL )
entities: 2582
entities: Outcome_Other
entities: patient preference
entities: 2583
entities: Outcome_Physical
entities: symptom/QOL
entities: 2584
entities: Outcome_Other
entities: patient preference
entities: 2585
entities: Outcome_Mental
entities: QOL
entities: 2586
entities: Participant_Condition
entities: breast cancer
entities: 2587
entities: Participant_Condition
entities: breast cancer
entities: 2588
entities: Participant_Condition
entities: chemotherapy-naïve patients with breast cancer
entities: 2589
entities: Participant_Sample-size
entities: 94
entities: 2590
entities: Participant_Sex
entities: women
entities: 2591
entities: Participant_Age
entities: 51 years ( range 27-76 )